Medication info
Hudiang 25 mg Tablet (Empagliflozin)

Hudiang 25 mg Tablet (Empagliflozin)

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin›25mg / 1 tablet
Manufacturer / importer
Huons Co., Ltd.
Appearance
Pale yellow oval film-coated tablet
Packaging
30 tablets/PTP [(10 tablets/PTPX3)], 10 tablets/PTP [(10 tablets/PTPX1)]
Approval status
Active

MFDS item code 202105424 · Approved 2021.07.16 · Insurance code 670609470

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The recommended dose of this medicine is 10 mg once daily as monotherapy or as add-on combination therapy with other glucose-lowering agents, including insulin. If 10 mg of this medicine is well tolerated and additional glycemic control is needed, the dose may be increased to 25 mg once daily. When this medicine is administered concomitantly with a sulfonylurea or insulin, a dose reduction of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, section 3. Adverse Reactions). This medicine may be taken with or without food. Swallow the tablet whole. If you miss a dose of this medicine, take it as soon as you remember. Do not take a double dose in one day. Special populations •Patients with renal impairment No dosage adjustment is necessary in patients with mild renal impairment. Treatment with this medicine should not be initiated in patients with a glomerular filtration rate (eGFR) below 60 ml/min/1.73m2 [or CrCl < 60 ml/min]. In patients who tolerate this medicine well but have a persistent glomerular filtration rate below 60ml/min/1.73m2 [or CrCl < 60 ml/min], the dose should be adjusted to or maintained at 10 mg once daily. This medicine should be discontinued if the glomerular filtration rate decreases to below 45 ml/min/1.73m2 [or CrCl < 45 ml/min]. Do not use this medicine in patients with end-stage renal disease (ESRD) or patients on dialysis, as efficacy is not expected. •Patients with hepatic impairment No dosage adjustment is necessary in patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment, as it has not been studied in this population. •Elderly patients No dosage adjustment is necessary based on age. In patients aged 75 years and older, renal function and the risk of volume depletion should be taken into consideration. Initiating treatment with this medicine is not recommended in patients aged 85 years and older because clinical experience is limited (see Precautions for Use, section 4. General Precautions).

Ingredients

Manufacturer
Huons Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes with difficulty in blood sugar control
  • cardiovascular disease
View approved original text

This medication is an adjunct used along with diet and exercise to help control blood sugar in adults with type 2 diabetes. It can be used alone or in combination with other medications. Caution is required when used in patients with type 2 diabetes who have difficulty controlling blood sugar, especially if there is a history of cardiovascular disease, and it is advisable to refer to related clinical trial information. This medication effectively improves blood sugar control and aids in diabetes management.

How to take

Adult dose

The recommended dose of this medicine is 10 mg once daily as monotherapy or as add-on combination therapy with other glucose-lowering agents, including insulin. If 10 mg of this medicine is well tolerated and additional glycemic control is needed, the dose may be increased to 25 mg once daily. When this medicine is administered concomitantly with a sulfonylurea or insulin, a dose reduction of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, section 3. Adverse Reactions). This medicine may be taken with or without food. Swallow the tablet whole. If you miss a dose of this medicine, take it as soon as you remember. Do not take a double dose in one day. Special populations •Patients with renal impairment No dosage adjustment is necessary in patients with mild renal impairment. Treatment with this medicine should not be initiated in patients with a glomerular filtration rate (eGFR) below 60 ml/min/1.73m2 [or CrCl < 60 ml/min]. In patients who tolerate this medicine well but have a persistent glomerular filtration rate below 60ml/min/1.73m2 [or CrCl < 60 ml/min], the dose should be adjusted to or maintained at 10 mg once daily. This medicine should be discontinued if the glomerular filtration rate decreases to below 45 ml/min/1.73m2 [or CrCl < 45 ml/min]. Do not use this medicine in patients with end-stage renal disease (ESRD) or patients on dialysis, as efficacy is not expected. •Patients with hepatic impairment No dosage adjustment is necessary in patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment, as it has not been studied in this population. •Elderly patients No dosage adjustment is necessary based on age. In patients aged 75 years and older, renal function and the risk of volume depletion should be taken into consideration. Initiating treatment with this medicine is not recommended in patients aged 85 years and older because clinical experience is limited (see Precautions for Use, section 4. General Precautions).

Precautions

This medication should not be used in patients with allergies to the active ingredient or any of the components. It is not to be administered to patients with type 1 diabetes or diabetic ketoacidosis due to potential danger. This medication is not expected to be effective in patients with severely impaired kidney function, end-stage renal disease, or those undergoing dialysis. This medication contains lactose, so it should not be used in patients with lactase deficiency, galactose intolerance, or genetic lactase enzyme deficiency. In patients with mildly impaired renal function, the dosage of this medication may need to be adjusted or discontinued, so regular monitoring of renal function is necessary. In patients with severe heart failure, the use of this medication is not recommended, requiring caution. When used in conjunction with insulin or insulin secretagogues, there may be an increased risk of hypoglycemia, and it may be necessary to reduce the doses of those medications as needed. This medication may cause side effects such as hypoglycemia, urinary tract infections, genital infections, increased urination, decreased fluid volume, hepatic dysfunction, etc., and any unusual symptoms should prompt immediate consultation with a healthcare professional. Particularly, serious metabolic imbalance known as ketoacidosis may occur, and immediate testing and treatment are required if symptoms like vomiting, abdominal pain, or difficulty in breathing arise. Elderly patients or those at risk of fluid loss should be cautious of dehydration or hypotension and should carefully monitor fluid status. This medication may affect kidney function, so kidney function tests are necessary before and during administration. It is recommended that breastfeeding women discontinue breastfeeding while taking this medication due to the possibility of the drug passing into breast milk. Pregnant women should avoid taking this medication, and if pregnancy is confirmed, administration should be discontinued. This medication may increase the risk of hypoglycemia while driving or operating machinery. In case of overdose, appropriate treatment should be provided based on clinical status, and there are no data on its removal through hemodialysis. This medication has not been established for safety and efficacy in children and adolescents under 18, and thus should not be used. There may be drug interactions, so healthcare providers should be informed of any other medications being taken. Regular monitoring of blood sugar and renal function tests is essential while on this medication.

Side effects

  • Hypoglycemia
  • ketoacidosis
  • vulvovaginitis
  • balanitis
  • other genital infections
  • urinary tract infections
  • perineal necrosis
  • pruritus
  • rash
  • urticaria
Show 12 more
  • angioedema
  • decreased fluid volume
  • increased urination
  • dysuria
  • interstitial nephritis
  • thirst
  • increased serum lipids
  • elevated serum creatinine
  • decreased glomerular filtration rate
  • increased hematocrit
  • urosepsis
  • pyelonephritis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. Additionally, it is important to maintain storage temperatures between 1 and 30 degrees Celsius (room temperature).

Appearance and packaging

Appearance

Pale yellow oval film-coated tablet

Package unit

30 tablets/PTP [(10 tablets/PTPX3)], 10 tablets/PTP [(10 tablets/PTPX1)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.